One of the most common leukemia in the world is chronic lymphocytic leukemia (CLL).
CLL, as an incurable malignant disorder of B-lymphocytes. CD200, formerly known as OX-
2, is a type I glycoprotein that is expressed on a variety of cell types. CD200 plays a vital
role in the modulation of the immune system and is upregulated on the surface of numerous
tumors, including chronic lymphocytic leukemia. In several studies, it is noted that CD200
was upregulated 1.6- to 5.4-fold in B cells from all patients with B-CLL and may suggest
that CD200 upregulation is an early event in the B-CLL disease process. It might conclude
that CD200 blocking therapy may be beneficial, and several studies have proven this. We can
conclude that CD200 is an excellent prognostic factor that expresses in most CLL patients,
and antiCD200 therapeutic interventions can be useful. This literature review article was
conducted with the purpose of role of CD200 Expression in the Diagnosis of Chronic
Lymphocytic Leukemia.
